
by Axis Securities Ltd (ASL) Research
Multi-cap Pharma stocks,where we expect strong growth in the earnings given the lower base in the past & recovery in US business.
Overall Pharma sector was under pressure in the past 2 years. However, we believe progressive improvement in business outlook, primarily driven by healthy growth in domestic business, normalization of price erosion in US business coupled with big ticket launches for selected companies, and favorable currency movement.
Unlock all metrics